Introduction : The present study aimed to compare cortical auditory maturation, as reflected by P1 latency of cortical auditory evoked potentials (CAEPs), in children with congenital severe-to-profound sensorineural hearing loss rehabilitated with unilateral cochlear implants (CIs) or bilateral conventional hearing aids (HAs). Materials and Methods: Eighty-five children with congenital severe-to-profound sensorineural hearing loss were included in this retrospective comparative study. Participants were divided into two groups: unilateral CI users (n = 42) and bilateral HA users (n = 43). All children were fitted with their devices before 48 months of age and achieved aided free-field thresholds between 30 and 50 dB HL. CAEPs were recorded using the Fonix® HEARLab System with speech stimuli (/m/, /g/, /t/) presented at 55 dB SPL. P1 latency values were measured and compared between groups using independent samples t-tests. Correlation analyses were performed to assess the relationship between duration of device use and P1 latency. Results: Eighty-five children were included (CI: n = 42; HA: n = 43). Mean P1 latency values did not differ significantly between groups for the /m/ stimulus (126.4 ± 29.13 ms vs. 126.4 ± 29.28 ms, p = 1.00), /g/ stimulus (106.5 ± 26.46 ms vs. 110.1 ± 29.49 ms, p = 0.55), or /t/ stimulus (114.7 ± 22.93 ms vs. 118.5 ± 27.19 ms, p = 0.48). Age at device fitting was comparable between groups (27.95 ± 9.10 vs. 26.88 ± 14.15 months, p = 0.68). The duration of device use was significantly longer in the HA group (48.02 ± 28.39 months) compared to the CI group (26.00 ± 15.92 months) (p < 0.001). Correlation analysis revealed no significant association between duration of device use and P1 latency for any stimulus (/m/: p = 0.28; /g/: p = 0.17; /t/: p = 0.09). Conclusions: When devices were fitted before 48 months of age and aided thresholds were optimized, unilateral cochlear implantation and bilateral conventional hearing aids showed comparable P1 latency values as an index of cortical auditory maturation. These findings suggest that early and adequate auditory stimulation may play an important role in supporting cortical auditory development in children with congenital hearing loss, although results should be interpreted within the context of individualized clinical management.
Sinonasal mucormycosis is an angioinvasive fungal infection associated with rapid local progression and substantial mortality. This study described the clinical characteristics of histopathologically confirmed sinonasal mucormycosis and evaluated baseline factors associated with all-cause 90-day mortality. This retrospective single-center cohort included 60 patients treated between January 2016 and March 2026. The primary outcome was all-cause mortality within 90 days of the index presentation. Exploratory adjusted associations were evaluated using Firth penalized logistic regression including age, hematological malignancy, neutrophil-to-lymphocyte ratio (NLR), and serum albumin. Radiological extent was not included in this model. A separate logistic model containing NLR and albumin only was evaluated for discrimination, with optimism assessed using 1000 bootstrap resamples. Twenty-two patients died within 90 days (36.7%). Non-survivors more frequently had hematological malignancy, corticosteroid exposure, neutropenia, and advanced radiological extension. In the adjusted model, higher NLR was associated with increased odds of mortality (adjusted odds ratio [aOR] per 5-unit increase, 1.45; 95% confidence interval [CI], 1.06–2.02; p = 0.023), whereas higher albumin was associated with lower odds of mortality (aOR per 0.5 g/dL increase, 0.72; 95% CI, 0.52–0.98; p = 0.039). The separate two-biomarker model had an apparent area under the receiver operating characteristic curve of 0.87 (95% CI, 0.78–0.95) and a bootstrap optimism-corrected value of 0.82. Higher baseline NLR and lower albumin were associated with all-cause 90-day mortality in this cohort. These exploratory findings do not establish prognostic value independent of anatomical extent or comprehensive clinical severity. Further evaluation and external validation are required before clinical application.